NY-ESTÉE-LAUDER
23.7.2024 23:01:30 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) (“ELC” or “the Company”) today announced that Akhil Shrivastava has been appointed Executive Vice President and Chief Financial Officer, succeeding Tracey T. Travis, whose intention to retire was announced on July 11, 2024. Akhil will report to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer, consistent with the reporting structure for Tracey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723453390/en/
The Estée Lauder Companies Names Akhil Shrivastava as Executive Vice President and Chief Financial Officer, Effective November 1, 2024 (Photo: Business Wire)
Akhil will assume his new role effective November 1, 2024. Tracey will remain at the Company until her retirement on June 30, 2025 to support a seamless transition.
“With over 25 years of extensive financial and leadership experience, Akhil is an exceptional and capable leader whose financial and strategic expertise and insights have been important in supporting the Company over the past several years, and he will be instrumental in driving forward our strategic direction and decisions,” said Fabrizio Freda. “I look forward to partnering with Akhil as we continue to rebuild stronger, more sustainable profitability and sales growth acceleration across the business.”
In his new role as Chief Financial Officer, Akhil will be responsible for the Company’s Global Finance, Accounting, Tax, Treasury, Investor Relations and New Business Development organizations. He will lead ELC’s Global Finance & Strategy (F&S) organization and will continue to cultivate and strengthen the tremendously talented Finance & Strategy Team, continuing to imbue agility and consumer-focus across the organization to drive sustainable value creation, governance, and strategic business objectives and priorities for the long-term.
Since joining ELC in 2015, Akhil has held several senior finance roles within the Company. He was recently named ELC’s Senior Vice President, Corporate Controller, a role that oversees Corporate Accounting and Financial Planning & Analysis, the International and Online Finance organizations, Pricing and Value Chain Finance, serving on both the Finance & Strategy Leadership Team and Executive Leadership Team. He also oversees the Operational Excellence pillar as part of the Profit Recovery and Growth Plan focused on driving strong inventory, cash, and cost improvements for the Company. Prior to his current role, he was Senior Vice President, Treasurer, where he was responsible for core Treasury functions, the Enterprise Risk Program, Real Estate, and oversight of the Company’s retirement funds.
Akhil will serve as a member of several of ELC’s senior management leadership groups including the Executive Leadership Team, Investment Development Committee, Fiduciary Investment Committee, and Corporate Risk Management Committee. In some cases, his membership will continue, and, in others, he will be a new member.
“Akhil has demonstrated his capabilities as a transformational, visionary, and collaborative leader who combines finance and strategy with an appreciation for the creativity within our business and our brands with consumers at the heart,” said William P. Lauder. “He also has a keen ability to cultivate high-performing teams and organizations and will continue to strengthen the tremendously talented Finance & Strategy organization, which will be instrumental in continuing to drive our strategic business objectives and priorities for the long-term.”
Akhil first joined ELC in 2015 as Vice President, Global Finance & Strategy for the Estée Lauder brand and was then appointed to the role of Senior Vice President, Global Finance & Strategy for Jane Hertzmark Hudis’ Brand Cluster in January 2019, where he provided strategic leadership and financial guidance while maximizing business and transformational opportunities across the brand cluster. Specifically, he helped allocate resources to support and promote the best growth opportunities from a consumer, sub-category, geography, and channel perspective.
He has also served as a valued member of many key enterprise initiatives at the Company, providing strategic financial direction for projects which include transforming ELC’s planning processes and capabilities to support the end-to-end business from consumer demand to delivery.
“With its leading portfolio of iconic brands, extensive global reach, and impressively talented people, I am honored to lead the Global Finance team,” said Akhil Shrivastava. “I look forward to helping to advance the Company’s multiple engines of growth to rebuild stronger, more sustainable profitability and support sales growth acceleration across brands, product categories, and regions while evolving the business for the future.”
Before joining The Estée Lauder Companies, Akhil spent eighteen years at Procter & Gamble, where he served in several finance and leadership roles across Asia, North America, and the global businesses, including Finance Director for Gillette, North America.
Akhil is a graduate of Engineering College in Rewa, India and has a Master’s Degree in Finance and Control from Delhi University.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include the various quotations related to rebuilding profitability and sales growth and the future of the finance and strategy function. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s profit recovery and growth plan and those described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2023. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723453390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
